Skip to main content
. 2023 Apr 20;10(17):2300552. doi: 10.1002/advs.202300552

Figure 4.

Figure 4

EVs‐mediated CRISPR/Cas9 system. The EVs can be engineered to target mutant genes or virus‐infected cells by fusing CD63 with GFP, while the loaded Cas9 proteins fused to the GFP nanobody. The delivery system can effectively inactivate target genes, inhibit tumor growth, and reduce virus replication rate.